Savara (SVRA) Convertible Debt (2016)
Savara (SVRA) reported Convertible Debt of $3.4 million for Q4 2016.
Savara (SVRA) has 1 years of Convertible Debt data on file, last reported at $3.4 million in Q4 2016.
- Quarterly Convertible Debt changed N/A year-over-year to $3.4 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $3.4 million (changed N/A YoY) and the FY2016 annual result came in at $3.4 million, changed N/A from the prior year.
- Convertible Debt held at $3.4 million in Q4 2016 per SVRA's latest filing.
- Across five years, Convertible Debt topped out at $3.4 million in Q4 2016 and bottomed at $3.4 million in Q4 2016.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 3.45 Mn |